Cargando…

Safety, efficacy, and response predictors of anticoagulation for the treatment of nonmalignant portal-vein thrombosis in patients with cirrhosis: a propensity score matching analysis

BACKGROUND/AIMS: Portal-vein thrombosis (PVT) develops in 10-25% of cirrhotic patients and may aggravate portal hypertension. There are few data regarding the effects of anticoagulation on nonmalignant PVT in liver cirrhosis. The aim of this study was to elucidate the safety, efficacy, and predictor...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Jung Wha, Kim, Gi Hyun, Lee, Jong Ho, Ok, Kyeong Sam, Jang, Eun Sun, Jeong, Sook-Hyang, Kim, Jin-Wook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association for the Study of the Liver 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278070/
https://www.ncbi.nlm.nih.gov/pubmed/25548745
http://dx.doi.org/10.3350/cmh.2014.20.4.384
_version_ 1782350463532793856
author Chung, Jung Wha
Kim, Gi Hyun
Lee, Jong Ho
Ok, Kyeong Sam
Jang, Eun Sun
Jeong, Sook-Hyang
Kim, Jin-Wook
author_facet Chung, Jung Wha
Kim, Gi Hyun
Lee, Jong Ho
Ok, Kyeong Sam
Jang, Eun Sun
Jeong, Sook-Hyang
Kim, Jin-Wook
author_sort Chung, Jung Wha
collection PubMed
description BACKGROUND/AIMS: Portal-vein thrombosis (PVT) develops in 10-25% of cirrhotic patients and may aggravate portal hypertension. There are few data regarding the effects of anticoagulation on nonmalignant PVT in liver cirrhosis. The aim of this study was to elucidate the safety, efficacy, and predictors of response to anticoagulation therapy in cirrhotic patients. METHODS: Patients with liver cirrhosis and nonmalignant PVT were identified by a hospital electronic medical record system (called BESTCARE). Patients with malignant PVT, Budd-Chiari syndrome, underlying primary hematologic disorders, or preexisting extrahepatic thrombosis were excluded from the analysis. Patients were divided into two groups (treatment and nontreatment), and propensity score matching analysis was performed to identify control patients. The sizes of the thrombus and spleen were evaluated using multidetector computed tomography. RESULTS: Twenty-eight patients were enrolled in this study between 2003 and 2014: 14 patients who received warfarin for nonmalignant PVT and 14 patients who received no anticoagulation. After 112 days of treatment, 11 patients exhibited significantly higher response rates (complete in 6 and partial in 5) compared to the control patients, with decreases in thrombus size of >30%. Compared to nonresponders, the 11 responders were older, and had a thinner spleen and fewer episodes of previous endoscopic variceal ligations, whereas pretreatment liver function and changes in prothrombin time after anticoagulation did not differ significantly between the two groups. Two patients died after warfarin therapy, but the causes of death were not related to anticoagulation. CONCLUSIONS: Warfarin can be safely administered to cirrhotic patients with nonmalignant PVT. The presence of preexisting portal hypertension is a predictor of nonresponse to anticoagulation.
format Online
Article
Text
id pubmed-4278070
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher The Korean Association for the Study of the Liver
record_format MEDLINE/PubMed
spelling pubmed-42780702014-12-29 Safety, efficacy, and response predictors of anticoagulation for the treatment of nonmalignant portal-vein thrombosis in patients with cirrhosis: a propensity score matching analysis Chung, Jung Wha Kim, Gi Hyun Lee, Jong Ho Ok, Kyeong Sam Jang, Eun Sun Jeong, Sook-Hyang Kim, Jin-Wook Clin Mol Hepatol Original Article BACKGROUND/AIMS: Portal-vein thrombosis (PVT) develops in 10-25% of cirrhotic patients and may aggravate portal hypertension. There are few data regarding the effects of anticoagulation on nonmalignant PVT in liver cirrhosis. The aim of this study was to elucidate the safety, efficacy, and predictors of response to anticoagulation therapy in cirrhotic patients. METHODS: Patients with liver cirrhosis and nonmalignant PVT were identified by a hospital electronic medical record system (called BESTCARE). Patients with malignant PVT, Budd-Chiari syndrome, underlying primary hematologic disorders, or preexisting extrahepatic thrombosis were excluded from the analysis. Patients were divided into two groups (treatment and nontreatment), and propensity score matching analysis was performed to identify control patients. The sizes of the thrombus and spleen were evaluated using multidetector computed tomography. RESULTS: Twenty-eight patients were enrolled in this study between 2003 and 2014: 14 patients who received warfarin for nonmalignant PVT and 14 patients who received no anticoagulation. After 112 days of treatment, 11 patients exhibited significantly higher response rates (complete in 6 and partial in 5) compared to the control patients, with decreases in thrombus size of >30%. Compared to nonresponders, the 11 responders were older, and had a thinner spleen and fewer episodes of previous endoscopic variceal ligations, whereas pretreatment liver function and changes in prothrombin time after anticoagulation did not differ significantly between the two groups. Two patients died after warfarin therapy, but the causes of death were not related to anticoagulation. CONCLUSIONS: Warfarin can be safely administered to cirrhotic patients with nonmalignant PVT. The presence of preexisting portal hypertension is a predictor of nonresponse to anticoagulation. The Korean Association for the Study of the Liver 2014-12 2014-12-24 /pmc/articles/PMC4278070/ /pubmed/25548745 http://dx.doi.org/10.3350/cmh.2014.20.4.384 Text en Copyright © 2014 by The Korean Association for the Study of the Liver http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Chung, Jung Wha
Kim, Gi Hyun
Lee, Jong Ho
Ok, Kyeong Sam
Jang, Eun Sun
Jeong, Sook-Hyang
Kim, Jin-Wook
Safety, efficacy, and response predictors of anticoagulation for the treatment of nonmalignant portal-vein thrombosis in patients with cirrhosis: a propensity score matching analysis
title Safety, efficacy, and response predictors of anticoagulation for the treatment of nonmalignant portal-vein thrombosis in patients with cirrhosis: a propensity score matching analysis
title_full Safety, efficacy, and response predictors of anticoagulation for the treatment of nonmalignant portal-vein thrombosis in patients with cirrhosis: a propensity score matching analysis
title_fullStr Safety, efficacy, and response predictors of anticoagulation for the treatment of nonmalignant portal-vein thrombosis in patients with cirrhosis: a propensity score matching analysis
title_full_unstemmed Safety, efficacy, and response predictors of anticoagulation for the treatment of nonmalignant portal-vein thrombosis in patients with cirrhosis: a propensity score matching analysis
title_short Safety, efficacy, and response predictors of anticoagulation for the treatment of nonmalignant portal-vein thrombosis in patients with cirrhosis: a propensity score matching analysis
title_sort safety, efficacy, and response predictors of anticoagulation for the treatment of nonmalignant portal-vein thrombosis in patients with cirrhosis: a propensity score matching analysis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4278070/
https://www.ncbi.nlm.nih.gov/pubmed/25548745
http://dx.doi.org/10.3350/cmh.2014.20.4.384
work_keys_str_mv AT chungjungwha safetyefficacyandresponsepredictorsofanticoagulationforthetreatmentofnonmalignantportalveinthrombosisinpatientswithcirrhosisapropensityscorematchinganalysis
AT kimgihyun safetyefficacyandresponsepredictorsofanticoagulationforthetreatmentofnonmalignantportalveinthrombosisinpatientswithcirrhosisapropensityscorematchinganalysis
AT leejongho safetyefficacyandresponsepredictorsofanticoagulationforthetreatmentofnonmalignantportalveinthrombosisinpatientswithcirrhosisapropensityscorematchinganalysis
AT okkyeongsam safetyefficacyandresponsepredictorsofanticoagulationforthetreatmentofnonmalignantportalveinthrombosisinpatientswithcirrhosisapropensityscorematchinganalysis
AT jangeunsun safetyefficacyandresponsepredictorsofanticoagulationforthetreatmentofnonmalignantportalveinthrombosisinpatientswithcirrhosisapropensityscorematchinganalysis
AT jeongsookhyang safetyefficacyandresponsepredictorsofanticoagulationforthetreatmentofnonmalignantportalveinthrombosisinpatientswithcirrhosisapropensityscorematchinganalysis
AT kimjinwook safetyefficacyandresponsepredictorsofanticoagulationforthetreatmentofnonmalignantportalveinthrombosisinpatientswithcirrhosisapropensityscorematchinganalysis